CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cadrenal Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.06−0.03 (-2.75%)
Close on Oct 19, 2026
- Market cap
- $3.09M
- P/E (TTM)
- –
- Dividend yield
- 1556.60%